Shah et al., 2018 - Google Patents
Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemiaShah et al., 2018
View HTML- Document ID
- 7844382509349836613
- Author
- Shah M
- Jorgensen J
- Saliba R
- Wang S
- Alousi A
- Andersson B
- Bashir Q
- Ciurea S
- Kebriaei P
- Marin D
- Patel K
- Popat U
- Rezvani K
- Rondon G
- Shpall E
- Champlin R
- Oran B
- Publication year
- Publication venue
- Biology of Blood and Marrow Transplantation
External Links
Snippet
We studied if the inclusion of early post–stem cell transplantation (SCT) minimal residual disease (MRD) assessments improved prognostication in patients with acute myeloid leukemia (AML). Two hundred sixty-nine AML patients in morphological complete remission …
- 208000007660 Residual Neoplasm 0 title abstract description 146
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia | |
| Zhou et al. | Pre-and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia | |
| Morita et al. | Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia | |
| Oran et al. | Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia | |
| Davids et al. | A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation | |
| Gökbuget et al. | Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia | |
| Nishiwaki et al. | Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: a study from the adult ALL WG of the JSHCT | |
| Araki et al. | Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease–based definition of complete remission? | |
| Yoshihara et al. | Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT | |
| Walter et al. | Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission | |
| Jabbour et al. | Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia | |
| Narita et al. | Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia | |
| Jacobsohn et al. | Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression | |
| Bar et al. | Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation | |
| Yoon et al. | BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core‐binding‐factor‐positive AML | |
| Guolo et al. | Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia | |
| Smith et al. | Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS | |
| Ravich et al. | Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel | |
| Leisch et al. | Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine–A retrospective single center experience | |
| Lee et al. | Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis | |
| Buccisano et al. | The prognostic significance of measurable (“Minimal”) residual disease in acute myeloid leukemia | |
| Prem et al. | Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment | |
| Abid et al. | Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with B cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation | |
| Wang et al. | Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T‐cell acute lymphoblastic leukaemia | |
| Muntañola et al. | Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome |